Henry Rodriguez, M.D.
Dr. Rodriguez joined the USF faculty in August, 2010 as a Professor of Pediatrics and Clinical Director of the USF Diabetes Center. He graduated from the Albany Medical College in NY in 1987. He completed his residency in Pediatrics at the University of Miami and Jackson Memorial Hospital in Miami in 1990 followed by fellowship training in Endocrinology at the University of California San Francisco. Upon completion of his fellowship in 1993, he joined the UCSF faculty as a Clinical Assistant Professor of Pediatrics and an Assistant Research Endocrinologist. Most recently he was an Associate Professor of Pediatrics in the section of Pediatric Endocrinology/Diabetology and the Director of the Pediatric Diabetes Clinical Program at the James Whitcomb Riley Hospital for Children between 1999 and 2010. There, he was local lead investigator on one national and two international multi-center trials investigating the causes of type 1 diabetes. Dr. Rodriguez has been an active contributor to the American Diabetes Association (ADA) and the Juvenile Diabetes Research Foundation (JDRF) on both local and national levels. His clinical and research interests focus on type 1 diabetes treatment, prevention and progress towards a cure.
Education & Training
| B.S. | Rensselaer Polytechnic Institute, 1985 |
| M.D. | Albany Medical College of Union University, 1987 |
| Pediatric Residency | University of Miami, Jackson Memorial Hospital, 1990 |
| Endocrinology Fellowship | University of California San Francisco, 1993 |
Board Certifications
Scholarly Activity
Dr. Rodriguez is an author of numerous scientific publications. He has been the recipient of numerous grants, particularly those related to type 1 diabetes.
Selected Publications
Phillip M, Battelino T, Rodriguez H, Danne T, Kaufman F; European Society for Paediatric Endocrinology; Lawson Wilkins Pediatric Endocrine Society; International Society for Pediatric and Adolescent Diabetes; American Diabetes Association; European Association for the Study of Diabetes: Use of insulin pump therapy in the pediatric age-group: consensus statement from the European Society for Paediatric Endocrinology, the Lawson Wilkins Pediatric Endocrine Society, and the International Society for Pediatric and Adolescent Diabetes, endorsed by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2007 Jun;30(6):1653-62.
Skyler JS, Greenbaum C J, Lachin JM, Leschek E, Rafkin-Mervis L, Savage P, Spain L, Type 1 Diabetes TrialNet Study Group [Rodriguez H – Study Group Member]: Type 1 Diabetes TrialNet--an international collaborative clinical trials network. Ann N Y Acad Sci. 2008 Dec;1150:14-24
Pescovitz MD, Greenbaum, CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran AM, Raskin P, Rodriguez H, Schatz DA, Wherrett D, Wilson DM, Lachin JM, and Skyler JS, for the Type 1 Diabetes TrialNet Anti-CD20 Study Group: Rituximab: B-Lymphocyte Depletion, and Preservation of Beta-Cell Function. N Eng J Med 2009;361:2143-52.
Johnson SB, Baughcum AE, Rafkin-Mervis LE, Schatz DA, for the DPT-1 Study Group: Rodriguez H – Study Group Member]: Participant and parent experiences in the oral insulin study of the Diabetes Prevention Trial for Type 1 Diabetes. Pediatric Diabetes 2009; 10:177-183.
Orban T, Sosenko JM, Cuthbertson D,Krischer JP,Skyler JS, Jackson R,Yu L, Palmer JP, Schatz DA, Eisenbarth GS, and the DPT-1 Study Group [Rodriguez H Study Group Member] Pancreatic Islet Cell Autoantibodies as Predictors of Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1). Diabetes Care 2009; 32:2269-2274.
Gottlieb PA, Quinlan S, Krause-Steinrauf H, Greenbaum CJ, Wilson DM, Rodriguez H, Schatz DA, Moran AM, Lachin JM, Skyler JS, and the TrialNet MMF/DZB Study Group [Rodriguez H – Study Group Member]: Failure to Preserve beta-cell function with Mycophenolate Mofetil and Daclizumab Combined Therapy in patients with New Onset Type 1 Diabetes. Diabetes Care 2010;33:826-832. PMID 20067954, PMCID: PMC2845036
